3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Phase 3
1
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Other hematologic neoplasm
1
Myeloid
1
Lymphoid
1
Conditions
Myelodysplastic Syndromes
9
Leukemia, Myeloid, Acute
9
Precursor Cell Lymphoblastic Leukemia-Lymphoma
5
Leukemia
4
Multiple Myeloma
3
Lymphoma
3
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
3
Leukemia, Lymphocytic, Chronic, B-Cell
3
Hematologic Neoplasms
3
Primary Myelofibrosis
2
Lymphoma, Non-Hodgkin
2
Leukemia, Myelomonocytic, Juvenile
2
Hodgkin Disease
2
Waldenstrom Macroglobulinemia
1
Sarcoma, Ewing
1
Rhabdoid Tumor
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Philadelphia Chromosome
1
Pathologic Complete Response
1
Neuroectodermal Tumors, Primitive
1
Neuroblastoma
1
Myeloid Diseases
1
Myasthenia Gravis
1
Medulloblastoma
1
Lymphoma, T-Cell, Peripheral
1
Lymphoma, T-Cell, Cutaneous
1
Lymphoma, T-Cell
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, Follicular
1
Interventions
venetoclax
6
Azacitidine
6
Cytarabine
5
fludarabine
4
Methotrexate
3
fludarabine phosphate
2
aldesleukin
2
RO6839921
2
Mitoxantrone
2
Interleukin-2
2
Granulocyte Colony-Stimulating Factor
2
Etoposide
2
Decitabine
2
Dasatinib
2
zileuton
1
thymoglobulin
1
spartalizumab
1
sabatolimab
1
quizartinib
1
pulrodemstat besilate
1
posaconazole
1
plerixafor
1
gilteritinib
1
etoposide phosphate
1
emvododstat
1
daratumumab
1
blinatumomab
1
Sorafenib
1
Sirolimus
1
Panobinostat
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Leukemia, Myeloid
×
thymoglobulin
×
Clear all
NCT02916979
2023-10-18
FluBuATG
Dartmouth-Hitchcock Medical Center
Phase 1
Completed
20 enrolled